Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 15 | 2022 | 1179 | 2.470 |
Why?
|
| Epigenesis, Genetic | 2 | 2015 | 163 | 0.920 |
Why?
|
| Heart Transplantation | 8 | 2017 | 328 | 0.850 |
Why?
|
| Vascular Resistance | 2 | 2017 | 179 | 0.680 |
Why?
|
| Physicians | 1 | 2022 | 324 | 0.670 |
Why?
|
| Holidays | 1 | 2018 | 3 | 0.650 |
Why?
|
| RNA, Long Noncoding | 2 | 2015 | 54 | 0.630 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2018 | 239 | 0.630 |
Why?
|
| Milrinone | 1 | 2017 | 12 | 0.620 |
Why?
|
| Stroke Volume | 3 | 2017 | 586 | 0.620 |
Why?
|
| Waiting Lists | 1 | 2017 | 104 | 0.580 |
Why?
|
| Regulatory Sequences, Ribonucleic Acid | 1 | 2015 | 3 | 0.550 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2015 | 117 | 0.510 |
Why?
|
| Hypertension, Pulmonary | 2 | 2020 | 232 | 0.500 |
Why?
|
| Chromatin | 1 | 2014 | 76 | 0.490 |
Why?
|
| MicroRNAs | 2 | 2015 | 447 | 0.470 |
Why?
|
| DNA | 1 | 2014 | 597 | 0.410 |
Why?
|
| Heart Ventricles | 1 | 2015 | 738 | 0.380 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2012 | 277 | 0.380 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2010 | 99 | 0.350 |
Why?
|
| Mitral Valve | 1 | 2010 | 166 | 0.340 |
Why?
|
| Myocarditis | 1 | 2007 | 49 | 0.300 |
Why?
|
| Cardiac Catheterization | 3 | 2020 | 419 | 0.290 |
Why?
|
| Humans | 22 | 2022 | 68525 | 0.250 |
Why?
|
| RNA | 2 | 2015 | 171 | 0.240 |
Why?
|
| Exercise Tolerance | 2 | 2012 | 75 | 0.230 |
Why?
|
| Hemodynamics | 4 | 2017 | 705 | 0.220 |
Why?
|
| Cardiology Service, Hospital | 1 | 2001 | 11 | 0.210 |
Why?
|
| Heart | 2 | 2018 | 850 | 0.210 |
Why?
|
| Quality Indicators, Health Care | 1 | 2001 | 136 | 0.190 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 102 | 0.180 |
Why?
|
| Middle Aged | 14 | 2020 | 21119 | 0.170 |
Why?
|
| Patient Readmission | 1 | 2001 | 267 | 0.170 |
Why?
|
| Diagnosis-Related Groups | 1 | 1998 | 28 | 0.170 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 1998 | 25 | 0.170 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 323 | 0.160 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1998 | 106 | 0.160 |
Why?
|
| Ventricular Function, Left | 2 | 1998 | 481 | 0.150 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 334 | 0.150 |
Why?
|
| Hospital Mortality | 1 | 1998 | 384 | 0.140 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 138 | 0.140 |
Why?
|
| Adult | 9 | 2020 | 21375 | 0.140 |
Why?
|
| RNA, Small Untranslated | 1 | 2015 | 1 | 0.140 |
Why?
|
| RNA, Small Nucleolar | 1 | 2015 | 2 | 0.140 |
Why?
|
| Biomarkers | 2 | 2015 | 1593 | 0.140 |
Why?
|
| Heart Rate | 1 | 1998 | 568 | 0.140 |
Why?
|
| Cellular Reprogramming | 1 | 2015 | 22 | 0.130 |
Why?
|
| Epigenomics | 1 | 2015 | 29 | 0.130 |
Why?
|
| Male | 14 | 2020 | 37281 | 0.130 |
Why?
|
| Female | 14 | 2020 | 38015 | 0.130 |
Why?
|
| Prognosis | 4 | 2007 | 2093 | 0.130 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1465 | 0.130 |
Why?
|
| Treatment Outcome | 8 | 2017 | 7028 | 0.130 |
Why?
|
| Genetic Markers | 1 | 2015 | 144 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 124 | 0.130 |
Why?
|
| Regeneration | 1 | 2015 | 105 | 0.120 |
Why?
|
| RNA Interference | 1 | 2015 | 266 | 0.120 |
Why?
|
| Ventricular Function, Right | 1 | 1995 | 103 | 0.120 |
Why?
|
| Tissue Engineering | 1 | 2015 | 212 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2015 | 195 | 0.110 |
Why?
|
| Exercise Test | 4 | 1998 | 242 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 498 | 0.110 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2012 | 25 | 0.110 |
Why?
|
| Systole | 1 | 2012 | 149 | 0.100 |
Why?
|
| Ethanol | 1 | 2018 | 892 | 0.100 |
Why?
|
| Animals | 3 | 2015 | 20877 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 785 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2007 | 772 | 0.090 |
Why?
|
| Follow-Up Studies | 5 | 2001 | 3256 | 0.090 |
Why?
|
| Sleep Apnea, Central | 1 | 2008 | 6 | 0.080 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2008 | 32 | 0.080 |
Why?
|
| Respiratory System | 1 | 2008 | 28 | 0.080 |
Why?
|
| Mycophenolic Acid | 1 | 2008 | 62 | 0.080 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2008 | 33 | 0.080 |
Why?
|
| Cardiovascular Infections | 1 | 2007 | 1 | 0.080 |
Why?
|
| Risk Factors | 2 | 2012 | 5719 | 0.080 |
Why?
|
| Ventricular Remodeling | 1 | 2010 | 318 | 0.070 |
Why?
|
| Graft Rejection | 2 | 2008 | 458 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 239 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 1998 | 349 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2017 | 7264 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 465 | 0.070 |
Why?
|
| Oxygen Consumption | 2 | 1998 | 258 | 0.070 |
Why?
|
| Aged | 5 | 2020 | 14842 | 0.070 |
Why?
|
| Atrial Flutter | 1 | 2004 | 16 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2020 | 3702 | 0.060 |
Why?
|
| Heart-Assist Devices | 1 | 2007 | 221 | 0.060 |
Why?
|
| Myocytes, Cardiac | 1 | 2007 | 442 | 0.060 |
Why?
|
| Quality of Life | 1 | 2012 | 1515 | 0.060 |
Why?
|
| Catheter Ablation | 1 | 2004 | 229 | 0.050 |
Why?
|
| Boston | 1 | 2001 | 35 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2001 | 4843 | 0.050 |
Why?
|
| Cardiology | 1 | 2001 | 140 | 0.050 |
Why?
|
| Apoptosis | 1 | 2007 | 1640 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2001 | 714 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 2550 | 0.040 |
Why?
|
| Hospitals, General | 1 | 1998 | 12 | 0.040 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 1998 | 33 | 0.040 |
Why?
|
| Massachusetts | 1 | 1998 | 28 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 1998 | 49 | 0.040 |
Why?
|
| New York | 1 | 1998 | 223 | 0.040 |
Why?
|
| Survival | 1 | 1998 | 22 | 0.040 |
Why?
|
| Heart Function Tests | 1 | 1998 | 33 | 0.040 |
Why?
|
| Cardiac Volume | 1 | 1997 | 21 | 0.040 |
Why?
|
| Cause of Death | 1 | 1998 | 241 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 1998 | 172 | 0.040 |
Why?
|
| Odds Ratio | 1 | 1998 | 880 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 1998 | 382 | 0.030 |
Why?
|
| Child | 1 | 2007 | 6400 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2008 | 1615 | 0.030 |
Why?
|
| Ventriculography, First-Pass | 1 | 1995 | 3 | 0.030 |
Why?
|
| Sodium Pertechnetate Tc 99m | 1 | 1995 | 5 | 0.030 |
Why?
|
| Life Tables | 1 | 1995 | 29 | 0.030 |
Why?
|
| Oxygen | 1 | 1997 | 386 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2077 | 0.030 |
Why?
|
| Logistic Models | 1 | 1998 | 1419 | 0.030 |
Why?
|
| Comorbidity | 1 | 1998 | 1425 | 0.030 |
Why?
|
| Age Factors | 1 | 1998 | 1860 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 1995 | 791 | 0.030 |
Why?
|
| Exercise | 1 | 1998 | 657 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 1996 | 514 | 0.030 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2008 | 2 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 2008 | 21 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2008 | 123 | 0.020 |
Why?
|
| Polysomnography | 1 | 2008 | 92 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 249 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1745 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1753 | 0.010 |
Why?
|
| Survival Rate | 2 | 1997 | 1055 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2004 | 601 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 4655 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 1998 | 187 | 0.010 |
Why?
|
| Muromonab-CD3 | 1 | 1996 | 8 | 0.010 |
Why?
|
| Pericarditis, Constrictive | 1 | 1996 | 4 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 1996 | 18 | 0.010 |
Why?
|
| Cardiac Output, Low | 1 | 1996 | 52 | 0.010 |
Why?
|
| Risk | 1 | 1997 | 563 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1996 | 99 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 1996 | 69 | 0.010 |
Why?
|
| Heart Arrest | 1 | 1996 | 113 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1996 | 222 | 0.010 |
Why?
|
| Biopsy | 1 | 1996 | 539 | 0.010 |
Why?
|
| Sex Factors | 1 | 1997 | 1265 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 1996 | 313 | 0.010 |
Why?
|
| Echocardiography | 1 | 1996 | 515 | 0.010 |
Why?
|
| Disease Progression | 1 | 1996 | 1037 | 0.010 |
Why?
|
| Incidence | 1 | 1996 | 1582 | 0.010 |
Why?
|
| Cohort Studies | 1 | 1997 | 2356 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 1996 | 866 | 0.010 |
Why?
|